# BIOPLEX 2200 SYPHILIS IgG 510(k) SUMMARY

This summary of $5 1 0 ( { \sf k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

<table><tr><td>510(k) Number</td><td>510(k) Summary Report Date</td></tr><tr><td>K063866</td><td>March 8, 2007</td></tr></table>

# MANUFACTURER INFORMATION

<table><tr><td rowspan=1 colspan=2>Manufacturer</td></tr><tr><td rowspan=1 colspan=1>Manufacturer Address</td><td rowspan=1 colspan=1>Bio-Rad Laboratories, Inc.Clinical Systems Division4000 Alfred Nobel DriveHercules, CA 94547</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>(510) 724-7000</td></tr><tr><td rowspan=1 colspan=1>Establishment Registration No.</td><td rowspan=1 colspan=1>2915274</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator</td><td rowspan=1 colspan=1>Bio-Rad Laboratories, Inc.4000 Alfred Nobel DriveHercules, CA 94547</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator No.</td><td rowspan=1 colspan=1>9929003</td></tr><tr><td rowspan=1 colspan=2>Official Correspondent for the BioPlex 2200 EBV IgG</td></tr><tr><td rowspan=1 colspan=1>Official Correspondent Address</td><td rowspan=1 colspan=1>Bio-Rad Laboratories6565 185th Ave NERedmond, WA 98052</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>425-881-8300</td></tr><tr><td rowspan=1 colspan=1>Establishment Registration No.</td><td rowspan=1 colspan=1>3022521</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator</td><td rowspan=1 colspan=1>Bio-Rad Laboratories6565 185th Ave NERedmond, WA 98052</td></tr><tr><td rowspan=1 colspan=1>Official Correspondent</td><td rowspan=1 colspan=1>Mr. Christopher Bentsen</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>(425) 498-1709</td></tr><tr><td rowspan=1 colspan=1>Fax</td><td rowspan=1 colspan=1>(425) 498-1651</td></tr></table>

# CLASSIFICATION INFORMATION

<table><tr><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>Treponema Pallidum Treponemal Test Reagents</td></tr><tr><td rowspan=1 colspan=1>Common Name:</td><td rowspan=1 colspan=1>Multi-Analyte Detection System Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>Product Trade Name</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG on the BioPlex 2200 Multi-AnalyteDetection System</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>Class II</td></tr><tr><td rowspan=1 colspan=1>Classification Panel</td><td rowspan=1 colspan=1>Microbiology</td></tr><tr><td rowspan=1 colspan=1>Regulation Number</td><td rowspan=1 colspan=1>866.3830</td></tr></table>

# LEGALLY MARKETED EQUIVALENT (SE) DEVICES

<table><tr><td rowspan=1 colspan=1>Comparative FDA ClearedPREDICATE DEVICE</td><td rowspan=1 colspan=1>510(k) Number</td><td rowspan=1 colspan=1>DecisionDate</td></tr><tr><td rowspan=1 colspan=1>Macro-Vue RPR Card (Becton Dickenson)</td><td rowspan=1 colspan=1>Pre-Amendment</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Serodia TPPA (Fujirebio Inc.)</td><td rowspan=1 colspan=1>971502</td><td rowspan=1 colspan=1>11/13/1997</td></tr><tr><td rowspan=1 colspan=1>Trep-Chek Anti-Treponemal EIA (Phoenix Bio-Tech Corp.)</td><td rowspan=1 colspan=1>001552</td><td rowspan=1 colspan=1>10/19/2000</td></tr></table>

# DEVICE DESCRIPTION

The Syphilis IgG kit uses multiplex flow immunoassay, a methodology that greatly resembles traditional ElA, but permits simultaneous detection and identification of many antibodies in a single tube.19 Three (3) different populations of dyed beads are coated with recombinant proteins associated with T. pallidum (15kD, 17kD and 47kD). The BioPlex 2200 System combines an aliquot of patient sample, sample diluent, and bead reagent into a reaction vessel. The mixture is incubated at $\mathsf { 3 7 ^ { \circ } C }$ After a wash cycle, anti-human IgG antibody, conjugated to phycoerythrin (PE), is added to the dyed beads, and this mixture is incubated at 37°C. The excess conjugate is removed in another wash cycle, and the beads are re-suspended in wash buffer. The bead mixture then passes through the detector. The identity of the dyed beads is determined by the fluorescence of the dyes, and the amount of antibody captured by the antigen is determined by the fluorescence of the attached PE. Raw data is calculated in relative fluorescence intensity (RFI).

Three additional dyed beads, Internal Standard Bead (ISB), Serum Verification Bead (SVB) and a Reagent Blank Bead (RBB) are present in each reaction mixture to verify detector response, the addition of serum or plasma to the reaction vessel and the absence of significant non-specific binding in serum or plasma. Refer to the BioPlex 2200 System Operation Manual for more information.

The system is calibrated using a set of four (4) distinct calibrators vials, supplied separately by Bio-Rad Laboratories. Four (4) vials representing two (2) or three (3) different antibody concentrations are used for calibration. Results are calculated for each of the three (3) antibodies and are compared against their own respective cut-off and are expressed as an antibody index (Al). A single result is reported after completing a composite analysis of all the antibodies (the highest Al value is reported).

# KIT COMPONENTS

Syphilis IgG (665-1450). The reagent pack contains supplies sufficient for 100 tests.

<table><tr><td rowspan=1 colspan=1>Vial</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>Bead Set</td><td rowspan=1 colspan=1>One (1) 10 mL vial, containing dyed beads coated with affinity-purified E.coli derived recombinant proteins to T. pallidum (15kD, 17kD, and 47kD),an Internal Standard (ISB), a Serum Verification (SVB), and a ReagentBlank (RBB), with Glycerol and protein stabilizers (bovine) in a MOPS (3-[NMorpholino] propanesulfonic acid) buffer. ProClin 300 (0.3%) and sodiumazide (&lt;0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>One (1) 5 mL vial, containing murine monoclonal anti-humanIgG/phycoerythrin conjugate and anti-human FXIl/phycoerythrin conjugate,with protein stabilizers (bovine) in a phosphate buffer. ProCline 300 (0.3%)and sodium azide (&lt;0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>Sample Diluent</td><td rowspan=1 colspan=1>One (1) 10 mL vial, containing protein stabilizers (bovine and murine) in atriethanolamine buffer. ProClino 300 (0.3%) and sodium azide (&lt;0.1%) aspreservatives.</td></tr></table>

ADDITIONAL REQUIRED ITEMS, AVAILABLE FROM BIO-RAD   

<table><tr><td rowspan=1 colspan=1>Catalog #</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>663-1400</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Calibrator Set: Four (4) 500 µL vials, containingT. pallidum (15kD, 17kD, and 47kD) antibodies in a human serum matrixmade from defibrinated plasma. ProClin® 300 (0.3%) as a preservative forall calibrators.</td></tr><tr><td rowspan=1 colspan=1>663-1430</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Control Set: Two (2) 1.5 mL vials of PositiveControl containing antibodies to T. pallidum 17kD and two (2) 1.5 mL vialsof Positive Control containing antibodies to T. pallidum 15kD and 47kD in ahuman serum matrix made from defibrinated plasma, and two (2) 1.5 mLvials of Negative Control in a human serum matrix made from defibrinatedplasma. ProClin® 300 (0.3%) as a preservative for all controls.</td></tr><tr><td rowspan=1 colspan=1>660-0817</td><td rowspan=1 colspan=1>BioPlex 2200 System Sheath Fluid: Two (2) 4 L bottles containingPhosphate Buffered Saline (PBS). ProClin® 300 (0.3%) and Sodium azide(0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0818</td><td rowspan=1 colspan=1>BioPlex 2200 System Wash Solution: One (1) 10 L bottle containingPhosphate Buffered Saline (PBS) and Tween 20. ProClin® 300 (0.3%) andSodium azide (0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0000</td><td rowspan=1 colspan=1>BioPlex 2200 Instrument and Software.</td></tr></table>

# INTENDED USE / INDICATIONS FOR USE

The Bio-Rad Syphilis IgG kit is a multiplex flow immunoassay intended for the qualitative detection of Treponema pallidum IgG antibodies in human serum. The test system, when used in conjunction with non-treponemal based assays, provides serological evidence of infection with $\tau .$ pallidum. This test system is also indicated for use in confirming reactive test results from nontreponemal based screening assays.

The Syphilis IgG kit is intended for use with the Bio-Rad BioPlex 2200 System.

The BioPlex 2200 Syphils IgG kit is not intended or use in screenig blood or plasa donors.

Warning: A positive result is not useful for establishing a diagnosis of Syphilis. In most situations, such a result may reflect prior treated infection; a negative result can exclude a diagnosis of syphilis except for incubating or early primary disease.

# TECHNOLOGICAL CHARACTERISTICS

The following tables summarize similarities and differences between the BioPlex 2200 Syphilis IgG Kit and the predicate devices used in comparative studies with the BioPlex 2200 Syphilis IgG Kit.

# A. BioPlex 2200 EBV IgG Assay VS. Predicate RPR Test

Table 1: Similarities between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents / Materials</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate RPR Test</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>The Bead Set reagent containingdyed antigen coated beads reacts withthe patient sample.</td><td rowspan=1 colspan=1>The Antigen Suspension reagentreacts with the patient sample.</td></tr></table>

Table 2: Similarities between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Similarities betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate RPR Test</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Aid in the diagnosis of Syphilis</td><td rowspan=1 colspan=1>Aid in the diagnosis of Syphilis</td></tr></table>

Table 3: Differences between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents / Materials</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate RPR Test</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead Set reagent - dyed antigencoated beads.</td><td rowspan=1 colspan=1>None.</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Conjugate, Sample Diluent, WashBuffer.</td><td rowspan=1 colspan=1>Antigen Suspension.</td></tr><tr><td rowspan=1 colspan=1>Sheath Fluid</td><td rowspan=1 colspan=1>Sheath Fluid is used to suspend thebead reagent and introduce it into thedetector.</td><td rowspan=1 colspan=1>Not similar; not utilized in RPRtests.</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Calibrators.</td><td rowspan=1 colspan=1>None.</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>Negative Control and multi-analytePositive Control.</td><td rowspan=1 colspan=1>User provided controls withestablished patterns of gradedactivity (optional Control Card Setsavailable).</td></tr></table>

Table 4: Differences between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Differences betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate RPR Test</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Multi-analyte qualitative detection ofhuman IgG antibodies to Treponemapallidum.</td><td rowspan=1 colspan=1>Non-treponemal qualitative andquantitative detection of humanreagin.</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum.</td><td rowspan=1 colspan=1>Serum and Plasma.</td></tr></table>

# B. BioPlex 2200 EBV IgG Assay VS. Predicate TPPA Test

Table 5: Similarities between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents / Materials</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate TPPA</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Sample Diluent</td><td rowspan=1 colspan=1>Sample Diluent</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Negative Control and multi-analytePositive Control</td><td rowspan=1 colspan=1>Non-reactive Control Serum andPositive Control Serum (containingrabbit antibodies to Treponemapallidum)</td></tr></table>

Table 6: Similarities between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Similarities betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate TPPA</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Aid in the diagnosis of Syphilis</td><td rowspan=1 colspan=1>Aid in the diagnosis of Syphilis</td></tr></table>

Table 7: Differences between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents / Materials</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate TPPA</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead reagent - dyed antigen coatedbeads.</td><td rowspan=1 colspan=1>None.</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Conjugate, Wash Buffer.</td><td rowspan=1 colspan=1>Sensitized Particles, UnsensitizedParticles.</td></tr><tr><td rowspan=1 colspan=1>Sheath Fluid</td><td rowspan=1 colspan=1>Sheath Fluid is used to suspend thebead reagent and introduce it into thedetector.</td><td rowspan=1 colspan=1>Not similar; not utilized in TPPAtests.</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Calibrators.</td><td rowspan=1 colspan=1>None.</td></tr></table>

Table 8: Differences between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Differences betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate TPPA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Multi-analyte detection of humanIgG antibodies to Treponemapallidum.</td><td rowspan=1 colspan=1>Detection of human antibodies toTreponema pallidum.</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum.</td><td rowspan=1 colspan=1>Serum and Plasma.</td></tr></table>

# BIO RAD

# C. BioPlex 2200 EBV IgG Assay vs. Predicate EIA Test

Table 9: Similarities between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents / Materials</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate EIA</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Wash Buffer, Sample Diluent</td><td rowspan=1 colspan=1>Sample Diluent, Wash Buffer</td></tr><tr><td rowspan=1 colspan=1>Calibrator(s)</td><td rowspan=1 colspan=1>CalibratorsF</td><td rowspan=1 colspan=1>Calibrator</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Negative Control and multi-analytePositive Control</td><td rowspan=1 colspan=1>Negative Control and PositiveControl</td></tr></table>

Table 10: Similarities between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Similarities betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate EIA</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to Treponema pallidum.</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to Treponema pallidum.</td></tr></table>

Table 11: Differences between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents / Materials</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate EIA</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead reagent - dyed antigen coatedbeads.</td><td rowspan=1 colspan=1>96 well microplate — antigen coatedmicrowells.</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Conjugate: Anti-human IgG /Phycoerythrin.</td><td rowspan=1 colspan=1>Conjugate: goat anti-human IgG /horseradish peroxidase, Substrate(TMB), Stop Solution.</td></tr><tr><td rowspan=1 colspan=1>Sheath Fluid</td><td rowspan=1 colspan=1>Sheath Fluid is used to suspend thebead reagent and introduce it into thedetector.</td><td rowspan=1 colspan=1>Not similar; not utilized in EIA&#x27;s.</td></tr></table>

Table 12: Diferens ete ragents with regar touncn nd u   

<table><tr><td rowspan=1 colspan=1>Differences betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 Syphilis IgG Kit</td><td rowspan=1 colspan=1>Predicate EIA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Multi-analyte detection of humanIgG antibodies to Treponemapallidum.</td><td rowspan=1 colspan=1>Detection of human IgG antibodiesto Treponema pallidum.</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum.</td><td rowspan=1 colspan=1>Serum and Plasma.</td></tr></table>

# PERFORMANCE SUMMARY

# A. Expected Values

# Prevalence

Expected values for the Syphilis IgG kit are presented by age and gender in the following tables for serum samples from unselected hospitalized patients $( N = 3 0 0 )$ , serum samples from patients who had a syphilis test ordered $( N = 5 0 0 )$ , and serum samples from unselected pregnant women $( N = 4 9 7 )$ . For all analytes, results of ${ \tt S O . 8 }$ Al are nonreactive, 0.9 and 1.0 Al are equivocal, and ${ \geq } 1 . 1$ Al are reported as reactive.

Table 13. Samples From Unselected Hospitalized Patients (N=300)   

<table><tr><td rowspan=3 colspan=1>Age</td><td rowspan=3 colspan=1>Gender</td><td rowspan=1 colspan=6>BioPlex 2200 Syphilis IgG</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Reactive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Nonreactive</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>0-9 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=2 colspan=1>10-19 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=2 colspan=1>20-29 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>94.7%</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=2 colspan=1>30-39 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>91.7%</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>90.0%</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=2 colspan=1>40-49 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10.7%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>89.3%</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>9.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>90.7%</td><td rowspan=1 colspan=1>43</td></tr><tr><td rowspan=2 colspan=1>50-59 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>92.6%</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>16.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>83.7%</td><td rowspan=1 colspan=1>43</td></tr><tr><td rowspan=2 colspan=1>60-69 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>91.7%</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>19.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>81.0%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=2 colspan=1>70-79 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>36.4%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>63.6%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>18.2%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>81.8%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=2 colspan=1>80-89 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=2 colspan=1>&gt; 89 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>25.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75.0%</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>11.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>267</td><td rowspan=1 colspan=1>89.0%</td><td rowspan=1 colspan=1>300</td></tr></table>

Table 14. Serum Samples From Patients Who Had a Syphilis Test Ordered (N=500)   

<table><tr><td rowspan=3 colspan=1>Age</td><td rowspan=3 colspan=1>Gender</td><td rowspan=1 colspan=6>BioPlex 2200 Syphilis IgG</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Reactive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Nonreactive</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%6</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>&lt; 10 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=2 colspan=1>10-19 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=2 colspan=1>20-29 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>96.0%</td><td rowspan=1 colspan=1>75</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>14,8%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>85.2%</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=2 colspan=1>30-39 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6.8%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>93.2%</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>10.9%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>84.8%</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=2 colspan=1>40-49 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>89.7%</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>27.5%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>78.5%</td><td rowspan=1 colspan=1>107</td></tr><tr><td rowspan=2 colspan=1>50-59 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>90.0%</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>26.5%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>72.1%</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=2 colspan=1>60-69 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>14.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>85.7%</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>18.8%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>81.3%</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=2 colspan=1>70-79 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>33.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>66.7%</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=2 colspan=1>80-89 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>14.2%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>426</td><td rowspan=1 colspan=1>85.2%</td><td rowspan=1 colspan=1>500</td></tr></table>

Table 15. Serum Samples From Unselected Pregnant Women (N=497)   

<table><tr><td rowspan=3 colspan=1>Age</td><td rowspan=1 colspan=6>BioPlex 2200 Syphilis IgG</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Reactive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Nonreactive</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>10-19 years of age</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>42</td></tr><tr><td rowspan=1 colspan=1>20-29 years of age</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>208</td><td rowspan=1 colspan=1>98.6%</td><td rowspan=1 colspan=1>211</td></tr><tr><td rowspan=1 colspan=1>30-39 years of age</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>193</td><td rowspan=1 colspan=1>98.5%</td><td rowspan=1 colspan=1>196</td></tr><tr><td rowspan=1 colspan=1>40-49 years of age</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>47</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>·1.2%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>491</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>497</td></tr></table>

# B. Reproducibility Studies

A reproducibility panel, consisting of seven (7) panel members for each of the three (3) recombinant proteins associated with T. pallidum (15kD, 17kD and 47kD) was prepared by BioRad Laboratories. Two (2) of the seven (7) members for each analyte had high positive levels of antibodies, and two (2) had positive antibody levels near the cutoff, additionally, there were two (2) high negative panel members and one (1) low negative panel member for each analyte. In addition, one positive control (antibody positive for 15kD and 47kD), one positive control antibody positive for 17kD) and a negative control (antibody negative for all analytes) were also tested. Reproducibility testing was performed at each of three (3) US testing facilities on a total of three lots of the Syphils IgGkit, three (3) lots of the Syphilis IgG Calibrator Set, and three (3)lots of the Syphilis IgG Control Set. Each testing facility evaluated reproducibility using one (1) kit lot of the Syphilis IgG kit with matched calibrators and controls. The panels were provided to each of the testing sites. Each of the seven (7) panel members and positive and negative controls was tested in duplicate $( \times 2 )$ o )s per ay  r (3) ays  c e 3)S facilities using one (1) lot of BioPlex 2200 Syphilis |gG Reagent Pack and one (1) lot of Syphilis IgG Calibrator Set (2 times x 2 runs x 3 days x 3 sites $= 3 6$ replicates per panel member and controls). The data were analyzed for intra-assay and inter-assay reproducibility according to the principles described in the Clinical Laboratory Standards Institute guidance EP5-A2, revised November 2004 and ISO/TR 22971:2205. The standard deviation (SD) and percent coefficient of variation $( \% C \vee )$ were calculated. Positive results can be found in Table 16.

Table 16. Reproducibility; BioPlex 2200 Syphilis IgG   

<table><tr><td rowspan=2 colspan=2>Syphilis IgGPanel Members</td><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>GrandMeanAI</td><td rowspan=1 colspan=2>withln-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site*</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SO</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=5 colspan=1>a00 to qawapied</td><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>10.4%</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>12.0%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>4.74%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>7.2%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>9.2%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>10.1%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>15.5%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>19.3%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>14.0%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>15.0%</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>23.3%</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>23.6%</td></tr><tr><td rowspan=5 colspan=1>Ctwapmed</td><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>7.9%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>9.79%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>8.2%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>9.9%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>9.3%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>9.4%</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>13.3%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>14.2%</td></tr><tr><td rowspan=5 colspan=1>ho o quawonpund</td><td rowspan=1 colspan=1>High Posltive 1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>7.8%</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>9.9%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>8.2%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>11.1%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>13.2%</td></tr><tr><td rowspan=1 colspan=1>Low Positie 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>11.9%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>13.3%</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>19.5%</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>19.9%</td></tr></table>

\*Between site variance includes between lot variance.

# C. Precision Studies

A precision panel, consisting of nine (9) panel members for each of the three (3) recombinant proteins associated with T. pallidum 5kD, 17kD and 47kD) was prepared by Bio-Rad Laboratories. Two (2) of the nine (9) panel members had high reactive levels of the ntibodies, two (2) had low reactive levels of the antibodies, and two (2) had antibody levels near the cut-off; additionally there were two (2) high negative panel members and one (1) low negative panel member for each analyte. Precision testing was performed at Bio-Rad Laboratories on one lot of the Syphilis gG kit,one lot of the Syphils IgG Calirator Set and one lot of the Syphilis IgG Control Set. Each of the nine (9) panel members was tested in duplicate $( \times 2 )$ on two (2) runs per day for twenty (20) days using one (1) lot of Syphilis IgG kit, one (1) lot of Syphilis IgG Calibrator Set and one (1) lot of Syphilis IgG Control Set (2 times $\times 2$ runs $\times 2 0 ~ \mathrm { d a y s } = 8 0$ replicates per panel member). The data were analyzed for intra-assay and inter-assay precision according to the principles described in the Clinical Laboratory Standards Institute guidance EP5-A2, revised November 2004 and ISO/TR 22971:2205. The standard deviation (SD) and percent coefficient of variation $( \% 0 \% )$ were calculated. Results can be found in Tables 17 - 19.

Table 17. Precision Results; BioPlex 2200 Syphilis IgG 15kD   

<table><tr><td rowspan=2 colspan=1>Syphilis 15kDPanel Members</td><td rowspan=2 colspan=1>SampleN^*</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>BO</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>NVA</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.6%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.6%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>8.3%</td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>9.6%</td></tr><tr><td rowspan=1 colspan=1>Near Cut-off 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>8.4%</td></tr><tr><td rowspan=1 colspan=1>Near Cut-off 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>7.8%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>8.6%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>10.4%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>7.9%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>9.6%</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>9.0%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>7.6%</td></tr></table>

N/A $\equiv$ No precision specification established for samples below cut-off.

Table 18. Precision Results; BioPlex 2200 Syphilis IgG 17kD   

<table><tr><td rowspan=2 colspan=1>Syphilis 17kDPanel Members</td><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>10.8%</td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>8.4%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>11.5%</td></tr><tr><td rowspan=1 colspan=1>Near Cut-off 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>7.9%</td></tr><tr><td rowspan=1 colspan=1>Near Cut-off 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>7.3%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>9.4%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>6.3%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>7.4%</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>8.2%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>9.1%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>7.1%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>8.2%</td></tr></table>

N/A $\approx$ No precision specification established for samples below cut-off.

Table 19. Precision Results; BioPlex 2200 Syphilis IgG 47kD   

<table><tr><td rowspan=2 colspan=1>Syphilis 47kDPanel Members</td><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>5.9%</td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>5.29%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>7.4%</td></tr><tr><td rowspan=1 colspan=1>Near Cut-off 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>5.7%</td></tr><tr><td rowspan=1 colspan=1>Near Cut-off 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>6.4%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>6.8%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>8.5%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>8.8%</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>6.29%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>7.0%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>6.3%</td></tr></table>

N/A = No precision specification established for samples below cut-off.

# DComparative Testing

Comparative Testing

Comparison of Syphilis IgG and Non-treponemal (RPR) and TPPA test The performance of the Syphilis IgG kit was evaluated against corresponding reference (RPR and TPPA) assays. Results were interpreted according to Table 20 below. Discordant samples were further tested by a treponemal EiA kit to determine the final result.

Table 20. Reference Syphilis Testing Algorithm   

<table><tr><td rowspan=1 colspan=1>Non-treponemalResult (RPR)</td><td rowspan=1 colspan=1>TreponemalResult (TPPA)</td><td rowspan=1 colspan=1>Reference AssaysResult</td><td rowspan=1 colspan=1>Treponemal (EIA)Result</td><td rowspan=1 colspan=1>Final ReferenceAssays Result</td></tr><tr><td rowspan=1 colspan=1>Nonreactive</td><td rowspan=1 colspan=1>Nonreactive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>Nonreactive</td><td rowspan=3 colspan=1>Reactive</td><td rowspan=3 colspan=1>Discordant</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Equivocal</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=3 colspan=1>Reactive</td><td rowspan=3 colspan=1>Nonreactive</td><td rowspan=3 colspan=1>Discordant</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Equivocal</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>Positive</td></tr></table>

A total of 1,750 serum samples were evaluated at three (3) U.S. clinical testing sites. The results can be observed in Tables 21 - 27 for banked serum samples from patients who had a syphilis test ordered; from unselected pregnant women; from serum samples requested to be RPR/TPPA reactive; from pregnant women requested to be treponemal assay positive; from pregnant women requested to be RPR/TPPA nonreactive; and from patients medically diagnosed with syphilis. For the purposes of percent agreement, reference assay equivocal results were assigned to the opposite result than that of the corresponding BioPlex 2200 Syphilis IgG result. Results are shown in Tables 21 - 27.

Table 21. Serum Samples From Patients Who Had a Syphilis Test Ordered $( N = 5 0 0 )$ EY   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>BioPlex 2200 Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>Reeed</td><td rowspan=1 colspan=1>Cecb</td><td rowspan=1 colspan=1>Noee</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(+) eagodWA</td><td rowspan=1 colspan=1>ce0three</td><td rowspan=1 colspan=1>-) a </td><td rowspan=1 colspan=1>coiectel</td></tr><tr><td rowspan=4 colspan=1>sAessy auajayBesd</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>46</td><td rowspan=4 colspan=1>100%(46/46)</td><td rowspan=4 colspan=1>92.0 - 100%</td><td rowspan=4 colspan=1>93.8%(426/454)</td><td rowspan=4 colspan=1>91.2 - 95.7%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>22*</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>426</td><td rowspan=1 colspan=1>451</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>426</td><td rowspan=1 colspan=1>500</td></tr></table>

\*Three (3) BioPlex 2200 Syphilis IgG reactive samples were RPR nonreactive, TPPA reactive and treponemal ElA equivocal. \*\* Of 2 samples with reactive results on the BioPlex 2200 Syphilis IgG assay, 16 were RPR and TPPA nonreactive, and 6 samples were RPR reactive, TPPA nonreactive and treponemal EIA negative.

Table 22. Unselected Serum Samples From Pregnant Women (N=497)   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>BioPlex 2200 Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>Reecce</td><td rowspan=1 colspan=1>Cel</td><td rowspan=1 colspan=1>Wm</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>() anutodawe %</td><td rowspan=1 colspan=1>cnTte</td><td rowspan=1 colspan=1>(-) ntaMn %</td><td rowspan=1 colspan=1>Ccta</td></tr><tr><td rowspan=4 colspan=1>Shee aoeeesHeset</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=4 colspan=1>100%(5/5)</td><td rowspan=4 colspan=1>56.5 - 100%</td><td rowspan=4 colspan=1>99.8%(491/492)</td><td rowspan=4 colspan=1>98.9 - 100.%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>491</td><td rowspan=1 colspan=1>492</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>491</td><td rowspan=1 colspan=1>497</td></tr></table>

\* One (1) sample with a BioPlex 2200 reactive result was RPR and TPPA nonreactive.

Table 23. Serum Samples Requested to be RPR and TPPA Reactive $( N = 2 5 0 )$   

<table><tr><td rowspan=2 colspan=4></td><td rowspan=1 colspan=6>Bio Plex 2200 Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>reeid</td><td rowspan=1 colspan=1>Boe</td><td rowspan=1 colspan=1>Noa</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(+) angisodken %</td><td rowspan=1 colspan=1>coc28ctar</td></tr><tr><td rowspan=4 colspan=2>shere RjyBesey</td><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=1>249</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>249</td><td rowspan=4 colspan=1>100%(249/249)</td><td rowspan=4 colspan=1>98.5 - 100%</td></tr><tr><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=2>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>249</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>250</td></tr></table>

Table 24. Serum Samples From Pregnant Women Requested to be Treponemal Assay Positive $( N = 1 8 3 )$ EMPY   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=6>BioPlex 2200 Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>Reeed</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>Noei</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>() anlnodkem %</td><td rowspan=1 colspan=1>Ci10ciaej</td></tr><tr><td rowspan=4 colspan=1>sers aejeyRestt</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>166</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>166</td><td rowspan=4 colspan=1>100%(166/166)</td><td rowspan=4 colspan=1>97.7-100%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>4*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>8**</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>183</td></tr></table>

\* Four ( 4) BioPlex 2200 Syphilis IgG reactive samples were RPR nonreactive, TPPA reactive and treponemal ElA equivocal. \*\* Of eight (8) BioPlex 2200 Syphilis IgG reactive samples, 1 sample was RPR and TPPA nonreactive and 7 were RPR reactive, TPPA nonreactive and treponemal EIA negative.

Table 25. Serum Samples From Pregnant Women Requested to be RPR/TPPA Nonreactive (N=250)   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=6>BioPlex 2200 Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>Reecle</td><td rowspan=1 colspan=1>Cel</td><td rowspan=1 colspan=1>Nodaol</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(+) agetaaawaby %</td><td rowspan=1 colspan=1>coiecte</td></tr><tr><td rowspan=4 colspan=1>sheh aaceeeyReset</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=4 colspan=1>98.8%(247/250)</td><td rowspan=4 colspan=1>96.5 -99.6%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=1>250</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=1>250</td></tr></table>

\* Three (3) BioPlex 2200 Syphilis IgG reactive samples were RPR and TPPA nonreactive.

Table 26. Combined Serum Samples From 183 Pregnant Women Requested to be Treponemal Assay Positive and 250 Pregnant Women Requested to be RPR/TPPA Nonreactive (N=433)   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>BioPlex 2200 Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>Reeeee</td><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>Nncee</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(+) ang!sodAa</td><td rowspan=1 colspan=1>Coce5thtt</td><td rowspan=1 colspan=1>(-) CnetaMame%</td><td rowspan=1 colspan=1>conee8ciee</td></tr><tr><td rowspan=4 colspan=1>she aayHesy</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>166</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>166</td><td rowspan=4 colspan=1>100%(166/166)</td><td rowspan=4 colspan=1>97.7 -100.0%</td><td rowspan=4 colspan=1>94.4%(252/267)</td><td rowspan=4 colspan=1>90.9 - 96.6%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>4*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>263</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>181</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>433</td></tr></table>

\*Four (4) BioPlex 2200 Syphilis IgG reactive samples were RPR reactive, TPPA nonreactive and treponemal ElA equivocal. \*\* Of 11 BioPlex 2200 Syphilis IgG reactive samples, 4 samples were RPR and TPPA nonreactive, and 7 samples were RPR nonreactive, TPPA reactive and treponemal EIA negative.

Table 27. Serum Samples From Patients Medically Diagnosed With Syphilis (N=70)   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=6>BioPlex 2200 Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>Reeeee</td><td rowspan=1 colspan=1>Ce</td><td rowspan=1 colspan=1>Noree</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>(+) ysodka</td><td rowspan=1 colspan=1>cine10tee</td></tr><tr><td rowspan=4 colspan=1>Srere ResBeset</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>63</td><td rowspan=4 colspan=1>100.0%(63/63)</td><td rowspan=4 colspan=1>94.2 - 100%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3**</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>70</td></tr></table>

\* One (1) sample with BioPlex 2200 Syphilis IgG reactive results was RPR nonreactive, TPPA reactive and treponemal ElA equivocal. \*\*Three (3) samples with BioPlex 2200 Syphilis IgG reactive results were RPR and TPPA nonreactive.

As can be seen in the table above, 95.7% (67/70) of the patients medically diagnosed with syphilis infection were reactive when tested with the BioPlex 2200 Syphilis IgG test, in comparison to 90% (63/70) by reference assay testing.

Correlation with Known HIV-1 Positive Samples

Performance of the BioPlex 2200 Syphilis IgG kit was evaluated in two hundred twenty (220) banked known HIV-1 positive serum samples. Results were compared to reference assay results for RPR/TPPA and if applicable, treponemal EIA.

Of the 220 known HIV-1 positive serum samples, one hundred eighty-one (181) were negative by reference assay testing and one hundred twenty-three (123) samples were negative by BioPlex 2200 Syphilis IgG testing, for $6 8 . 0 \%$ (123/181) negative agreement with a $9 5 \%$ confidence interval of $6 0 . 8 – 7 4 . 3 \%$ Of the one hundred eighty-one (181) samples, 4 samples were equivocal by reference assay testing (and were considered negative for the purposes of percent agreement calculations) and nineteen (19) samples were equivocal by BioPlex 2200 Syphilis IgG testing (and were considered positive for the purposes of percent agreement calculations).

Of the 220 known HIV-1 positive serum samples, thirty-nine (39) were positive by reference assay testing and by BioPlex 2200 Syphilis IgG testing, for $100 \%$ (39/39) positive agreement with a $9 5 \%$ confidence interval of $9 1 . 0 \substack { - 1 0 0 \% }$ .

Correlation with Disease Stages and Clinical Sensitivity   
The performance of the Syphilis IgG kit was evaluated at one clinical testing site using a CDC panel of banked frozen characterized sera $( N = 1 4 0 )$ , with known disease state and treatment status. Panel samples were from treated and untreated patients with primary, secondary or latent infections. Performance of the Syphilis IgG kit for the CDC panel was compared to reference asy results usi comercially availabl RPR, TPA an i requird treponemal EIA) kits y known clinical status. Results are shown in Tables 28 - 30 below.

Tabe BioPlex 200 Syphilis IgG vs. Reference Assays: Comparison by Known Clinical tatus   

<table><tr><td rowspan=4 colspan=2>KnownClinicalStatus</td><td rowspan=1 colspan=9>Reference Assays Result</td><td rowspan=4 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>Positive</td><td rowspan=1 colspan=3>Equivocal</td><td rowspan=1 colspan=3>Negative</td></tr><tr><td rowspan=1 colspan=3>BioPlex 2200Syphilis IgG</td><td rowspan=1 colspan=3>BioPlex 2200Syphilis IgG</td><td rowspan=1 colspan=3>BioPlex 2200Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>EQV</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>EQV</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>EQV</td><td rowspan=1 colspan=1>NR</td></tr><tr><td rowspan=3 colspan=1>iinetee</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>O</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=3 colspan=1>tetee</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>140</td></tr></table>

Table 29. Bio-Rad Syphilis IgG vs. a CDC Panel of Characterized Sera (N=140)   

<table><tr><td rowspan=2 colspan=2>Known ClinicalStatus</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=5>BioPlex 2200 Syphilis IgG</td><td rowspan=1 colspan=5>Reference Assays Result</td></tr><tr><td rowspan=1 colspan=1>Bee</td><td rowspan=1 colspan=1>Ce</td><td rowspan=1 colspan=1>Noe</td><td rowspan=1 colspan=1>% Stcii</td><td rowspan=1 colspan=1>Coeecieea</td><td rowspan=1 colspan=1>Gotitid</td><td rowspan=1 colspan=1>e</td><td rowspan=1 colspan=1>Nee</td><td rowspan=1 colspan=1>% SiCi</td><td rowspan=1 colspan=1>cpine0teae</td></tr><tr><td rowspan=3 colspan=1>in e</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>83.3%(10/12)</td><td rowspan=1 colspan=1>55.2 - 95.3%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>83.3%(10/12)</td><td rowspan=1 colspan=1>55.2 - 95.3%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(10/10)</td><td rowspan=1 colspan=1>72.2 - 100%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(10/10)</td><td rowspan=1 colspan=1>72.2 - 100%</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>61.5%(8/13)</td><td rowspan=1 colspan=1>35.5 - 82.3%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>61.5%(8/13)</td><td rowspan=1 colspan=1>35.5 - 82.3%</td></tr><tr><td rowspan=3 colspan=1>iee</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>93.8%(15/16)</td><td rowspan=1 colspan=1>71.6 - 98.9%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>93.8%(15/16)</td><td rowspan=1 colspan=1>71.6 - 98.9%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(36/36)</td><td rowspan=1 colspan=1>90.3 - 100%</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%36/36)</td><td rowspan=1 colspan=1>90.3 - 100%</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>92.5%(49/53)</td><td rowspan=1 colspan=1>82.1 - 97.0%</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>92.5%(49/53)</td><td rowspan=1 colspan=1>82.1 - 97.0%</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>91.4%(128/140)</td><td rowspan=1 colspan=1>85.6 - 95.0%</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>91.4%(128/140)</td><td rowspan=1 colspan=1>85.6 - 95.0%</td></tr></table>

Table 30. BioPlex 2200 Syphilis IgG vs. Reference Assays: Percent Agreement by Known Clinical Status   

<table><tr><td rowspan=1 colspan=2>Known Clinical Status</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=2>Positive Agreement</td><td rowspan=1 colspan=1>95% Confidence Interval</td></tr><tr><td rowspan=3 colspan=1>pa</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>(10/10)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>72.2 - 100%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>(10/10)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>72.2 - 100%</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>(8/8)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>67.5 - 100%</td></tr><tr><td rowspan=3 colspan=1>teee</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>(15/15)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>79.6 - 100%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>(36/36)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90.3 - 100%</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>(49/49)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>91.8 - 100%</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>(128/128)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.1 - 100%</td></tr></table>

The performance of the Syphilis $\mathsf { I g G }$ kit was raal banked prospectively collected serum samples from treated and untreated patients with primary and secondary syphilis infections $( N = 1 0 )$ .Performance of the Syphilis $\mathsf { I g G }$ kit in the 10 samples was compared to a corresponding composite result using commercially available (RPR, TPPA and if required treponemal ElA) kits by known clinical status. Results are shown in Tables 31 - 33 below.

Table 31. BioPlex 2200 Syphilis IgG vs. Reference Assays: Comparison by Known Clinical Status   

<table><tr><td rowspan=4 colspan=2>KnownClinicalStatus</td><td rowspan=1 colspan=9>Reference Assays Result</td><td rowspan=4 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>Positive</td><td rowspan=1 colspan=3>Equivocal</td><td rowspan=1 colspan=3>Negative</td></tr><tr><td rowspan=1 colspan=3>BioPlex 2200Syphilis IgG</td><td rowspan=1 colspan=3>BioPlex 2200Syphilis IgG</td><td rowspan=1 colspan=3>BioPlex 2200Syphilis IgG</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>EQV</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>EQV</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>EOV</td><td rowspan=1 colspan=1>NR</td></tr><tr><td rowspan=2 colspan=1>enetn</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>iiean</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td></tr></table>

Table 32. Bio-Rad Syphilis IgG vs. Prospectively Collected Serum Samples With Known Clinical Status $( N = 1 0 )$   

<table><tr><td rowspan=2 colspan=2>Known ClinicalStatus</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=5>BioPtex 2200 Syphilis IgG</td><td rowspan=1 colspan=5>Reference Assays Result</td></tr><tr><td rowspan=1 colspan=1>Rere</td><td rowspan=1 colspan=1>Be</td><td rowspan=1 colspan=1>Noaon</td><td rowspan=1 colspan=1>AnsCenite</td><td rowspan=1 colspan=1>cie</td><td rowspan=1 colspan=1>asgsod</td><td rowspan=1 colspan=1> n</td><td rowspan=1 colspan=1>teetie</td><td rowspan=1 colspan=1>% hnaisCiic</td><td rowspan=1 colspan=1>ce[tna un</td></tr><tr><td rowspan=2 colspan=1>piae</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(1/1)</td><td rowspan=1 colspan=1>20.6 - 100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.0%(0/1)</td><td rowspan=1 colspan=1>N/A*</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA*</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>N/A*</td></tr><tr><td rowspan=2 colspan=1>ieee</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(2/2</td><td rowspan=1 colspan=1>34.2 - 100%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(2/2)</td><td rowspan=1 colspan=1>34.2 - 100%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(717)</td><td rowspan=1 colspan=1>64.5 - 100%</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(7/7)</td><td rowspan=1 colspan=1>64.5 - 100%</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(10/10)</td><td rowspan=1 colspan=1>72.2 - 100%</td><td rowspan=1 colspan=1>g</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>90.0%(9/10)</td><td rowspan=1 colspan=1>59.5 - 98.2%</td></tr></table>

\* In cases where agreement resulted in a numerator of zero $( 0 )$ , $9 5 \%$ confidence interval could not be calculated; in cases where agreement resulted in $( 0 / 0 )$ samples, percent agreement and $9 5 \%$ confidence interval could not be calculated.

Table 33. BioPlex 2200 Syphilis IgG vs. Reference Assays: Percent Agreement by Known Clinical Status   

<table><tr><td rowspan=1 colspan=2>Known Clinical Status</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=2>Positive Agreement</td><td rowspan=1 colspan=1>95% Confidence Interval</td></tr><tr><td rowspan=2 colspan=1>pinanen</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>N/A*</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>NA*</td><td rowspan=1 colspan=1>N/A*</td></tr><tr><td rowspan=2 colspan=1>eee</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>(2/2)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>34.2 - 100%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>(7/7)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>64.5 - 100%</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>(9/9)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>70.1 - 100%</td></tr></table>

\* In cases where agreement resulted in (0/0) samples percent agreement and $9 5 \%$ confidence intervals could not be calculated.

The results from testing the CDC panel of samples from patients with treated and untreated primary, secondary and latent syphilis infections $( N = 1 4 0 )$ ; and the banked prospectively collected samples from treated and untreated patients with primary and secondary syphilis infections $( N = 1 0 )$ , were combined and results are presented in Tables $3 4 - 3 6$ below.

Table 34. BioPlex 2200 Syphilis IgG vs. Reference Assays: Combined Comparison By Known Clinical Status   

<table><tr><td rowspan=4 colspan=2>KnownClinicalStatus</td><td rowspan=1 colspan=9>Reference Assays Result</td><td rowspan=4 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>Positive</td><td rowspan=1 colspan=3>Equivocal</td><td rowspan=1 colspan=3> Negative</td></tr><tr><td rowspan=1 colspan=3>BioPlex 2200Syphilis IgG</td><td rowspan=1 colspan=3>BioPlex 2200Syphilis IgG</td><td rowspan=1 colspan=3>BioPlex 2200Syphilis lgG</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>EOV</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>EQV</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>EQV</td><td rowspan=1 colspan=1>NR</td></tr><tr><td rowspan=3 colspan=1>hne</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=3 colspan=1>ieea</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>43</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>150</td></tr></table>

Table 35. BioPlex 2200 Syphilis IgG vs. Combined CDC Panel and Prospectively Collected Samples With Known Clinical Status $( N = 1 5 0 )$ EY   

<table><tr><td rowspan=2 colspan=2>Known ClinicalStatus</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=5>BioPlex 2200 Syphilis IgG</td><td rowspan=1 colspan=5>Reference Assays Result</td></tr><tr><td rowspan=1 colspan=1>Regraee</td><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>Noa</td><td rowspan=1 colspan=1>%lceic</td><td rowspan=1 colspan=1>colie[aul</td><td rowspan=1 colspan=1>reee</td><td rowspan=1 colspan=1>e</td><td rowspan=1 colspan=1>Noeie</td><td rowspan=1 colspan=1>%tCii</td><td rowspan=1 colspan=1>coudn0C</td></tr><tr><td rowspan=3 colspan=1>tineet</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>84.6%(11/13)</td><td rowspan=1 colspan=1>57.8 - 95.7%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>76.9%(10/13)</td><td rowspan=1 colspan=1>49.7 - 91.8%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(10/10)</td><td rowspan=1 colspan=1>72.2 - 100%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(10/10)</td><td rowspan=1 colspan=1>72.2 - 100%</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>61.5%(8/13)</td><td rowspan=1 colspan=1>35.5 - 62.3%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>61.5%(8/13)</td><td rowspan=1 colspan=1>35.5 - 82.3%</td></tr><tr><td rowspan=3 colspan=1>ieee</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>94.4%(17/18)</td><td rowspan=1 colspan=1>74.2 - 99.0%</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>94.4%(17/18)</td><td rowspan=1 colspan=1>74.2 - 99.0%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(43/43)</td><td rowspan=1 colspan=1>91.8 - 100%</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(43/43)</td><td rowspan=1 colspan=1>91.8 - 100%</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>92.5%(49/53)</td><td rowspan=1 colspan=1>82.1 - 97.0%</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>92.5%(49/53)</td><td rowspan=1 colspan=1>82.1 - 97.0%</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>92.0%(138/150)</td><td rowspan=1 colspan=1>86.5 - 95.4%</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>89.5%(137/150)</td><td rowspan=1 colspan=1>86.5 - 94.9%</td></tr></table>

n as whee gre ult  /spe snsiv $9 5 \%$ confidence intervals couldo calculated.

Table 36. BioPlex 2200 Syphilis IgG vs. Reference Assays: Combined Percent Agreement By Known Clinical Status   

<table><tr><td rowspan=1 colspan=2>Known Clinical Status</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=2>Positive Agreement</td><td rowspan=1 colspan=1>95%ConfidenceInterval</td></tr><tr><td rowspan=3 colspan=1>nneeae</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>(10/10)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>72.2 - 100%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>(10/10)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>72.2 - 100%</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>(8/8)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>67.5 - 100%</td></tr><tr><td rowspan=3 colspan=1>teea</td><td rowspan=1 colspan=1>Primary</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>(17/17)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>81.6 - 100%</td></tr><tr><td rowspan=1 colspan=1>Secondary</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>(43/43)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>91.8 - 100%</td></tr><tr><td rowspan=1 colspan=1>Latent</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>(49/49)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>92.7 - 100%</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>(137/137)</td><td rowspan=1 colspan=1>1009</td><td rowspan=1 colspan=1>97.3 - 100%</td></tr></table>

Diagnostic Screening Results   
The results presented in the preceding tables demonstrate that BioPlex 2200 Syphilis IgG can be used for the qualitative detection of antibodies to Treponema pallidum in human serum when used as a diagnostic screening test. BioPlex 2200 Syphilis IgG Reactive Samples   
In the banked purchased requested to be RPR/TPPA reactive samples $( N = 2 5 0 )$ , 249 samples were BioPlex 2200 Syphilis IgG reactive. Of those 249 samples, $100 \%$ (249/249) were RPR reactive.

• In the banked purchased samples from unselected pregnant women $( N = 4 9 7$ , 6 samples were Bolex 0 Shilis acive $3 3 . 3 \%$ (2/6) were RPR reactive.

n e banke samples from patients with a syphilis tet order $( N = 5 0 0$ , 71 samples were BioPlex 2200 Syphilis IgG reactive. Of those 71 samples, $2 8 . 2 \%$ (20/71) were RPR reactive.

In the banked purchased samples from pregnant women requested to be treponemal assay positive $( N = 1 8 3 )$ ,178 samples were BioPlex 2200 Syphilis IgG reactive. Of those 178 samples, $2 4 . 7 \%$ (44/178) were RPR reactive.

• In the banked purchased samples from pregnant women requested to be RPR/TPPA nonreactive $( N = 2 5 0 )$ , 3 of the samples were BioPlex 2200 Syphilis IgG reactive. Of those 3 samples, none were RPR reactive.

: In the banked prospectively collected samples from patients with medically diagnosed syphilis infections $( N = 7 0 )$ ,67 of the samples were BioPlex 2200 Syphilis IgG reactive. Of those 67 samples, $8 6 . 6 \%$ (58/67) were RPR reactive.

In the CDC panel of well characterized samples from treated or untreated patients with primary, secondary or latent syphilis infection $( N = 1 4 0 )$ ,18 of the samples were BioPlex 2200 Syphilis IgG reactive. Of those 128 samples, $9 9 . 2 \%$ 27/128) were RPR reactive.

In the banked prospectively collected samples from treated or untreated patients with primary or secondary syphilis infection $( N = 1 0 )$ ,0of the samples were BioPlex 2200 Syphilis IgG reactive. Of those 10 samples, $100 \%$ $( 1 0 / 1 0 )$ were RPR reactive.

Diagnostic Confirmatory Results

Results from testing with the BioPlex 2200 Syphilis IgG are presented below to demonstrate its utility as a diagnostic confirmatory test. This test also confirms reactive results from nontreponemal based screening assays.

RPR Reactive Samples

In the banked purchased samples from unselected pregnant women $\scriptstyle ( N = 4 9 7$ , 4 samples were RPR reactive. Of those 4 samples, $50 \%$ (2/4) were TPPA reactive and $50 \%$ (2/4) were BioPlex 2200 Syphilis IgG reactive.

•In the banked purchased requested to be RPR/TPPA reactive samples $( N = 2 5 0 )$ , 250 samples were RPR reactive. Of those 250 samples, $9 9 . 6 \%$ (249/250) were TPPA reactive and $9 9 . 6 \%$ (249/250) were BioPlex 2200 Syphilis IgG reactive.

In the banked samples from patients with a syphilis test ordered $( N = 5 0 0$ , 20 samples were RPR reactive. Of those 20 samples, $90 \%$ (18/20) were TPPA reactive and $100 \%$ (20/20) were BioPlex 2200 Syphilis IgG reactive.

•In he banked purchased samples from pregnant women requested to be treponemal assay positive $( N = 1 8 3 )$ samples were RPR reactiv.Of those 44 samples, $100 \%$ (44/44) were reactive with the TPPA and $100 \%$ ) we cve with e Bioex 0 Shl G test.

• In the banked purchased samples from pregnant women requested to be RPR/TPPA nonreactive $( N = 2 5 0 )$ ,3  the samples were RPR reactive. None of the samples were TPPA or BioPlex 2200 Syphilis IgG reactive.

: In the banked prospectively collected samples from patients with medically diagnosed syphilis infections $( N = 7 0 )$ the samples were RPR reactive. Of those 8 samples, $100 \%$ (58/58) were reactive with the TPPA and 100% (58/58) were reactive with the BioPlex 2200 Syphilis IgG test.

In the CDC panel of well characterized samples from treated or untreated patients with primary, secondary or latent syphilis inetio $( N { = } 1 4 0 )$ 8 f the samples were RPR reactive. Of those 138 samples, 92% (127/138) were reactive with TPPA and 92% (127/138) were reactive with the BioPlex 2200 Syphilis IgG test.

In the banked prospectively collected samples from treated or untreated patients with primary or secondary syphilis infection $( N = 1 0 )$ the samples were reactive. Of those 0 samples, $90 \%$ (9/10) were TPPA reactive and $100 \%$ $( 1 0 / 1 0 )$ were BioPlex 2200 Syphilis IgG reactive.

# E. Cross-Reactivity

A cross-reactivity study was performed to determine if samples from various disease states and other potentially interfering factors interfere with test results when tested with the BioPlex 2200 Syphilis IgG kit. A panel of ten (10) specimens positive for each cross reactant were evaluated for possible cross reactivity with he Biolex 2200 Syphils gkit.he test specimens were lso evaluated by TPPA, and where BioPlex 2200 Syphilis IgG results did not agree with TPPA, samples were further tested by RPR and a commercially available EIA. The results demonstrated that the various disease state samples evaluated do not cross react with the BioPlex 2200 Syphilis IgG kit. Most of the samples evaluated were high positive for each disease state. The majority of all samples that elicited a positive result were also confirmed positive by the another tremal antiody test A), indicating reactivity  Syphilis. pallidum) IgGantis rather than cross reactivity. Results can be found in Table 37.

Table 37. Cross-Reactivity   

<table><tr><td rowspan=1 colspan=1>CrossReactives</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Syphills IgG</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>CrossReactives</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Syphillis kgG</td></tr><tr><td rowspan=3 colspan=1>ANA</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BloPlex 2200</td><td rowspan=1 colspan=1>3</td><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>AheumatoidFactor</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>dsDNA</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>CMV IgG</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>HCV</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>3</td><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>HIV</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>E. COR</td><td rowspan=3 colspan=1>4*11</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>HTLV</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>HSV-1 1gG</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>1</td><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>Pregnantwomen</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>Lyme IgGBorreliaburgdorferi</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BloPlex 2200</td><td rowspan=1 colspan=1>1</td><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>HSV-2 lgG</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BloPlex 2200</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>VZV IgG</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>Lyme IgGAfzelli / Garni</td><td rowspan=3 colspan=1>49&quot;t</td><td rowspan=1 colspan=1>BioPtex 2200</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>Hyper-gamma-globullnemia</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>2</td><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>EBV IgG</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>Leptospirosis</td><td rowspan=3 colspan=1>7</td><td rowspan=1 colspan=1>BioPlex2200</td><td rowspan=1 colspan=1>2</td><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>Sm all Pox</td><td rowspan=3 colspan=1>10tt1</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>TPPA</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td></tr></table>

\* Due to limited availability of samples, only four E. coli specimens were evaluated. \*\* Additional samples were tested to evaluate the various lyme strains. Only positive samples were tested by the predicate. t† Sample was negative by TPPA but positive by both RPR and EIA tt† Testing was only performed on the BioPlex 2200 Syphilis IgG assay.

Mr. David Bhend Regulatory Affairs Associate Bio-Rad Laboratories Diagnostics Group $6 5 6 \bar { 5 } ~ 1 8 5 ^ { \mathrm { t h } }$ Avenue NE Redmond, WA 98052

Re: k063866 Trade/Device Name: BioPlex 2200 Syphilis IgG kit on the BioPlex 2200 Multi-Analyte Detection System Regulation Number: 21 CFR 866.3830 Regulation Name: Treponema pallidum treponemal test reagents Regulatory Class: Class II Product Code: LIP Dated: March 8, 2007 Received: March 9, 2007

Dear Mr. Bhend:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) prearet notifiatin.The Afnding substantial euivalence  yourdevice  a ly marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Jall, an

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): k063866

Device Name:

# BioPlex 2200 Syphilis IgG kit on the BioPlex 2200 Multi-Analyte Detection System

# Indications for Use:

The Bio-Rad Syphilis IgG kit is a multiplex flow immunoassay intended for the qualitative detection of Treponema pallidum IgG antibodies in human serum. The test system, when used in conjunction with non-treponemal based assays, provides serological evidence of infection with T. pallidum. This test system is also indicated for use in confirming reactive test results from non-treponemal based screening assays.

The Syphilis IgG kit is intended for use with the Bio-Rad BioPlex 2200 System.

The BioPlex 2200 Syphilis IgG kit is not intended for use in screening blood or plasma donors.

Warning: A positive result is not useful for establishing a diagnosis of Syphilis. In most situations, such a result may reflect prior treated infection; a negative result can exclude a diagnosis of syphilis except for incubating or early primary disease.

Prescription Use: X (Per 21 CFR 801.109)

AND/OR Over-The-Counter Use: (Optional Format 1-2-96)

![](images/8bb002c1bf7e69a94d82f6d07e235abd62a5c3f5fa804b53420e606018c95009.jpg)

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K663866